These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1413661)

  • 1. Red cell and platelet concentrates from blood collected into half-strength citrate anticoagulant: improved maintenance of red cell 2,3-diphosphoglycerate in half-citrate red cells.
    Farrugia A; Douglas S; James J; Whyte G
    Vox Sang; 1992; 63(1):31-8. PubMed ID: 1413661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood components in the treatment of acute blood loss: use of freeze-preserved red cells, platelets, and plasma proteins.
    Valeri CR
    Anesth Analg; 1975; 54(1):1-14. PubMed ID: 1090205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the procurement of blood coagulation factor VIII. In vitro studies on blood components prepared in half-strength citrate anticoagulant 18 hours after phlebotomy.
    Griffin B; Bell K; Prowse C
    Vox Sang; 1988; 55(1):9-13. PubMed ID: 3138819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro effect on stored red blood cells and platelets after a 15-hour delayed refrigeration of whole blood prior to component preparation in CPD-AD.
    Koerner K; Sahlmen P; Stampe D
    Vox Sang; 1986; 50(3):141-5. PubMed ID: 3716287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and laboratory experience with erythrocyte and platelet preparations from a 0.5CPD Erythro-Sol opti system.
    Högman CF; Eriksson L; Wallvik J; Payrat JM
    Vox Sang; 1997; 73(4):212-9. PubMed ID: 9407638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Half-strength citrate CPD and new additive solutions for improved blood preservation. I. Studies of six experimental solutions.
    Högman CF; Eriksson L; Gong J; Payrat JM; Debrauwere J
    Transfus Med; 1993 Mar; 3(1):43-50. PubMed ID: 8038896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Storage of red cell concentrates in CPD-A2 for 42 and 49 days.
    Beutler E; West C
    J Lab Clin Med; 1983 Jul; 102(1):53-62. PubMed ID: 6854134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-week red cell storage with preservation of 2,3 DPG.
    Carmen RA; Sohmer PR; Leng BS; Moore GL; Nelson EJ; Simon TL; Myhre BA; Marcus CS; Moroff G; Lewis LM
    Transfusion; 1988; 28(2):157-61. PubMed ID: 3354043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of biochemical changes occurring during storage of red cells. Comparative studies with CPD and CPDA-1 anticoagulant-preservative solutions.
    Moroff G; Dende D
    Transfusion; 1983; 23(6):484-9. PubMed ID: 6649025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival and biochemical characteristics of stored red cells preserved with citrate-phosphate-dextrose-adenine-one and two and prepared from whole blood maintained at 20 to 24 degrees C for eight hours following phlebotomy.
    Moroff G; Morse EE; Katz AJ; Kahn RA; Dende D; Swatman L; Staggs SD
    Transfusion; 1984; 24(2):115-9. PubMed ID: 6710583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the procurement of blood coagulation factor VIII in vitro studies on blood components prepared in half-strength citrate anticoagulant.
    Prowse C; Waterston YG; Dawes J; Farrugia A
    Vox Sang; 1987; 52(4):257-64. PubMed ID: 3114954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of an additive solution for preservation of canine red blood cells.
    Wardrop KJ; Owen TJ; Meyers KM
    J Vet Intern Med; 1994; 8(4):253-7. PubMed ID: 7983619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved red blood cell storage using optional additive systems (OAS) containing adenine, glucose and ascorbate-2-phosphate.
    Moore GL; Ledford ME; Brummell MR
    Transfusion; 1981; 21(6):723-31. PubMed ID: 7314223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dihydroxyacetone, pyruvate, and phosphate effects on 2,3 DPG and ATP in citrate-phosphate-dextrose-adenine blood preservation.
    Dawson RB; Fagan DS; Meyer DR
    Transfusion; 1984; 24(4):327-9. PubMed ID: 6464157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Half-strength citrate CPD combined with a new additive solution for improved storage of red blood cells suitable for clinical use.
    Högman CF; Eriksson L; Gong J; Högman AB; Vikholm K; Debrauwere J; Payrat JM; Stewart M
    Vox Sang; 1993; 65(4):271-8. PubMed ID: 8310679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of irradiation on red cells stored in CPDA-1 and CPD-ADSOL (AS-1).
    Jeter EK; Gadsden RH; Cate J
    Ann Clin Lab Sci; 1991; 21(3):177-86. PubMed ID: 1905899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole blood storage in citrate and phosphate solutions containing half-strength trisodium citrate: cellular and biochemical studies.
    Mishler JM; Darley JH; Cederholm-Williams S; Wright G
    J Pathol; 1978 Mar; 124(3):125-39. PubMed ID: 722376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buffy-coat-derived platelet concentrates prepared from half-strength citrate CPD and CPD whole-blood units. Comparison between three additive solutions: in vitro studies.
    Gulliksson H; Eriksson L; Högman CF; Payrat JM
    Vox Sang; 1995; 68(3):152-9. PubMed ID: 7625071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo viability studies of two additive solutions in the postthaw preservation of red cells held for 3 weeks at 4 degrees C.
    Moore GL; Hess JR; Ledford ME
    Transfusion; 1993 Sep; 33(9):709-12. PubMed ID: 8212114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinical evaluation of citrate-phosphate-dextrose-adenine blood.
    Kreuger A; Akerblom O; Högman CF
    Vox Sang; 1975; 29(2):81-9. PubMed ID: 807039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.